![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Bioequivalence of a darunavir/cobicistat
fixed-dose combination tablet versus single agents in healthy volunteers
|
|
|
Reported by Jules Levin
14th Clinical Pharmacology Workshop in HIV April 22-24 2013 Amsterdam
Thomas N Kakuda,1 Tom Van De Casteele,2 Romana Petrovic,2 Magda Opsomer,2 Frank Tomaka,1 Richard MW Hoetelmans2
1Janssen Research & Development LLC, Titusville, NJ, USA; 2Janssen Infectious Diseases BVBA, Beerse, Belgium
![Pharm1.gif](../images/052613/052613-2/Pharm1.gif)
![Pharm2.gif](../images/052613/052613-2/Pharm2.gif)
![Pharm3.gif](../images/052613/052613-2/Pharm3.gif)
![Pharm4.gif](../images/052613/052613-2/Pharm4.gif)
![Pharm5.gif](../images/052613/052613-2/Pharm5.gif)
![Pharm6.gif](../images/052613/052613-2/Pharm6.gif)
![Pharm7.gif](../images/052613/052613-2/Pharm7.gif)
![Pharm8.gif](../images/052613/052613-2/Pharm8.gif)
![Pharm9.gif](../images/052613/052613-2/Pharm9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|